Pfizer says Phase 3 MagnetisMM-5 trial meets primary endpoint for ELREXFIO in myeloma

Pfizer

Pfizer

PFE

0.00
  • Pfizer reported positive interim topline results from Phase 3 MagnetisMM-5 trial of ELREXFIO in relapsed or refractory multiple myeloma patients who had received at least one prior treatment line.
  • Study met primary endpoint, showing ELREXFIO kept disease under control longer than standard regimen of daratumumab, pomalidomide, dexamethasone.
  • Safety profile matched prior experience, with no new safety signals flagged.
  • Results have not yet been presented; detailed findings will be submitted for presentation at a future medical congress.
  • Trial continues to evaluate overall survival, which remains a key secondary endpoint.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604290645BIZWIRE_USPR_____20260428_BW420063) on April 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.